Skip to main
ALMS

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc. presents a positive outlook due to its promising pipeline, particularly with ESK-001, which has demonstrated significant efficacy and safety data in treating moderate to severe plaque psoriasis, showing substantial improvements in patient-reported outcomes. The company is also increasing its terminal growth rate from 2% to 3%, reflecting a historical trend in expanded drug utility over time, which could positively impact long-term revenue prospects. Additionally, Alumis' lead candidate, envudeucitinib, aims to attain superior efficacy and safety in multiple autoimmune indications, underscoring the company's potential to address substantial unmet medical needs in a growing market.

Bears say

Alumis Inc faces significant regulatory risks that could adversely affect its financial projections, as the success of its clinical trials does not guarantee product approval, which is critical for achieving revenue. The company also contends with competition from established products, highlighted by a recent decline in efficacy metrics, indicating potential challenges in differentiating its therapies from others in the market. Furthermore, logistical challenges, such as the administration requirements for icotrokinra, add to concerns regarding patient compliance, which could impact market adoption and overall commercial success.

Alumis Inc (ALMS) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Alumis Inc (ALMS) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.